Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company's portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company's FemVue device for in-office ultrasound-based evaluation.

Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is focused on equipping OB/GYNs and other women's health practitioners with in-office solutions. The newly CE Mark approved FemHSG Catheter and FemVue device are designed to support a comprehensive initial fertility workup. FemaSeed®, the Company's first-line fertility treatment, represents the next step in the care pathway, supporting access to earlier, more cost-effective intervention.